Terms: = Ovarian cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864
173 results:
1. Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations.
Liu D; Cao M; Wang H; Cao W; Zheng C; Li Y; Wang Y
BMC Med; 2024 Mar; 22(1):137. PubMed ID: 38528540
[TBL] [Abstract] [Full Text] [Related]
2. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract] [Full Text] [Related]
3. Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions.
Chien YW; Wang Y; Huang P; Lawson BC; Kolin DL; Chui MH; Vang R; Numan TA; Soong TR; Wang BG; Smith SA; Chen CL; Stone R; Douville C; Wang TL; Shih IM
Am J Surg Pathol; 2024 Apr; 48(4):475-486. PubMed ID: 38298022
[TBL] [Abstract] [Full Text] [Related]
4. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers.
Payton M; Belmontes B; Hanestad K; Moriguchi J; Chen K; McCarter JD; Chung G; Ninniri MS; Sun J; Manoukian R; Chambers S; Ho SM; Kurzeja RJM; Edson KZ; Dahal UP; Wu T; Wannberg S; Beltran PJ; Canon J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Minocherhomji S; Bourbeau MP; Allen JR; Coxon A; Tamayo NA; Hughes PE
Nat Cancer; 2024 Jan; 5(1):66-84. PubMed ID: 38151625
[TBL] [Abstract] [Full Text] [Related]
5. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract] [Full Text] [Related]
6. Aneuploidy Landscape in Precursors of ovarian cancer.
Wang Y; Douville C; Chien YW; Wang BG; Chen CL; Pinto A; Smith SA; Drapkin R; Chui MH; Numan T; Vang R; Papadopoulos N; Wang TL; Shih IM
Clin Cancer Res; 2024 Feb; 30(3):600-615. PubMed ID: 38048050
[TBL] [Abstract] [Full Text] [Related]
7. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
8. Morphological Changes of the ovarian Vein in Pelvic Venous Disorders.
Nykonenko A; Trailin A; Lazarashvili Z; Proczka RM; Havrylenko B; Nykonenko O
Eur J Vasc Endovasc Surg; 2024 Mar; 67(3):500-505. PubMed ID: 37952635
[TBL] [Abstract] [Full Text] [Related]
9. Association of plasma branched-chain amino acid with multiple cancers: A mendelian randomization analysis.
Xu H; Wang X; Xu X; Liu L; Zhang Y; Yan X; Zhang Y; Dang K; Li Y
Clin Nutr; 2023 Dec; 42(12):2493-2502. PubMed ID: 37922693
[TBL] [Abstract] [Full Text] [Related]
10. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
[TBL] [Abstract] [Full Text] [Related]
11. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
[TBL] [Abstract] [Full Text] [Related]
12.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract] [Full Text] [Related]
13. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing cancers.
DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
[TBL] [Abstract] [Full Text] [Related]
14. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
15. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract] [Full Text] [Related]
16. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.
Cunnea P; Curry EW; Christie EL; Nixon K; Kwok CH; Pandey A; Wulandari R; Thol K; Ploski J; Morera-Albert C; McQuaid S; Lozano-Kuehne J; Clark JJ; Krell J; Stronach EA; McNeish IA; Bowtell DDL; Fotopoulou C
Cell Rep Med; 2023 Jun; 4(6):101055. PubMed ID: 37220750
[TBL] [Abstract] [Full Text] [Related]
17. ccne1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis.
Zheng X; Chen L; Liu W; Zhao S; Yan Y; Zhao J; Tian W; Wang Y
Hereditas; 2023 Mar; 160(1):13. PubMed ID: 36964635
[TBL] [Abstract] [Full Text] [Related]
18. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Foster KI; Shaw KRM; Jin J; Westin SN; Yap TA; Glassman DM; Jazaeri AA; Rauh-Hain JA; Lee S; Fellman BM; Ju Z; Liu Y; Fleming ND; Sood AK
Cancer; 2023 Jun; 129(11):1672-1680. PubMed ID: 36930815
[TBL] [Abstract] [Full Text] [Related]
19. Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review.
Schutte T; Embaby A; Steeghs N; van der Mierden S; van Driel W; Rijlaarsdam M; Huitema A; Opdam F
Cancer Treat Rev; 2023 Apr; 115():102531. PubMed ID: 36893690
[TBL] [Abstract] [Full Text] [Related]
20. Mesonephric-like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas.
Mirkovic J; Olkhov-Mitsel E; Amemiya Y; Al-Hussaini M; Nofech-Mozes S; Djordjevic B; Kupets R; Seth A; McCluggage WG
Histopathology; 2023 Jun; 82(7):978-990. PubMed ID: 36860193
[TBL] [Abstract] [Full Text] [Related]
[Next]
